Autolus Therapeutics (NASDAQ:AUTL) Now Covered by Bryan, Garnier & Co

Investment analysts at Bryan, Garnier & Co initiated coverage on shares of Autolus Therapeutics (NASDAQ:AUTL – Get Rating) in a research report issued to clients and investors on Friday, Briefing.com reports. The firm set a “buy” rating and a $5.00 price target on the stock. Bryan, Garnier & Co’s target price points to a potential upside of 139.23% from the company’s previous close.

AUTL has been the topic of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Autolus Therapeutics in a research report on Tuesday, March 7th. Mizuho reduced their price objective on Autolus Therapeutics from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, March 8th.

Autolus Therapeutics Trading Down 2.3 %

Shares of AUTL stock opened at $2.09 on Friday. Autolus Therapeutics has a 12 month low of $1.60 and a 12 month high of $4.73. The stock has a 50-day moving average price of $1.99 and a 200 day moving average price of $2.34.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers grew its position in Autolus Therapeutics by 8.3% during the first quarter. Cetera Investment Advisers now owns 124,300 shares of the company’s stock worth $518,000 after buying an additional 9,550 shares in the last quarter. Nantahala Capital Management LLC raised its position in Autolus Therapeutics by 6.6% during the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock valued at $18,124,000 after purchasing an additional 268,818 shares during the last quarter. UBS Group AG raised its position in Autolus Therapeutics by 716.1% during the 1st quarter. UBS Group AG now owns 73,858 shares of the company’s stock valued at $308,000 after purchasing an additional 64,808 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Autolus Therapeutics by 144.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company’s stock worth $1,566,000 after acquiring an additional 222,093 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Autolus Therapeutics in the 2nd quarter worth approximately $36,000. 70.06% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

(Get Rating)

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.